BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Perazella MA, Reilly RF. Imaging patients with kidney disease: how do we approach contrast-related toxicity? Am J Med Sci 2011;341:215-21. [PMID: 21139495 DOI: 10.1097/MAJ.0b013e3181f016e6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Raman FS, Nacif MS, Cater G, Gai N, Jones J, Li D, Sibley CT, Liu S, Bluemke DA. 3.0-T whole-heart coronary magnetic resonance angiography: comparison of gadobenate dimeglumine and gadofosveset trisodium. Int J Cardiovasc Imaging 2013;29:1085-94. [PMID: 23515949 DOI: 10.1007/s10554-013-0192-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
2 Fretellier N, Idée J, Bruneval P, Guerret S, Daubiné F, Jestin G, Factor C, Poveda N, Dencausse A, Massicot F, Laprévote O, Mandet C, Bouzian N, Port M, Corot C. Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. Br J Pharmacol 2012;165:1151-62. [PMID: 21740412 DOI: 10.1111/j.1476-5381.2011.01585.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
3 Perazella MA. Pharmacology behind Common Drug Nephrotoxicities. Clin J Am Soc Nephrol 2018;13:1897-908. [PMID: 29622670 DOI: 10.2215/CJN.00150118] [Cited by in Crossref: 54] [Cited by in F6Publishing: 19] [Article Influence: 13.5] [Reference Citation Analysis]
4 Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, Bauer WR. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:31. [PMID: 22607376 DOI: 10.1186/1532-429X-14-31] [Cited by in Crossref: 62] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]